Market Place
Sourcing Support
BioXcel Therapeutics Announces Proposed Public Offering
21 Nov 2024 //
GLOBENEWSWIRE
BioXcel Therapeutics Reports Third Quarter 2024 Financial Results
14 Nov 2024 //
GLOBENEWSWIRE
BioXcel Therapeutics to Report Q3 2024 Financial Results on Nov 14
08 Nov 2024 //
GLOBENEWSWIRE
BioXcel Therapeutics to Present at ThinkEquity Conference
29 Oct 2024 //
GLOBENEWSWIRE
BioXcel Therapeutics Announces Update On BXCL501 Programs
19 Sep 2024 //
GLOBENEWSWIRE
BioXcel Therapeutics Initiates SERENITY At-Home Trial
05 Sep 2024 //
GLOBENEWSWIRE
BioXcel Therapeutics To Participate In Canaccord Genuity Growth Conference
07 Aug 2024 //
GLOBENEWSWIRE
BioXcel Therapeutics Reports Second Quarter 2024 Financial Results
06 Aug 2024 //
GLOBENEWSWIRE
BioXcel Therapeutics To Report Q2 2024 Results On August 6
30 Jul 2024 //
GLOBENEWSWIRE
BioXcel Announces Preliminary Q2 IGALMI Net Revenues
16 Jul 2024 //
GLOBENEWSWIRE
BioXcel TAnnounces Positive Results from PRN Treatment Study for Agitation
25 Jun 2024 //
GLOBENEWSWIRE
BioXcel Therapeutics to Present at Jefferies Global Healthcare Conference
28 May 2024 //
GLOBENEWSWIRE
BioXcel Announces ASCP 2024 Oral, Poster Presentations
21 May 2024 //
GLOBENEWSWIRE
BioXcel Therapeutics Reports First Quarter 2024 Financial Results
09 May 2024 //
GLOBENEWSWIRE
BioXcel to Report First Quarter 2024 Financial Results on May 9, 2024
25 Apr 2024 //
GLOBENEWSWIRE
BioXcel`s BXCL701+KEYTRUDA in PDAC Data at ASCO 2024
24 Apr 2024 //
GLOBENEWSWIRE
BioXcel Plans BXCL501 At-Home Setting Evaluation
22 Apr 2024 //
GLOBENEWSWIRE
BioXcel Therapeutics Announces TRANQUILITY Trial Plan for BXCL501
10 Apr 2024 //
GLOBENEWSWIRE
BioXcel Therapeutics Announces $25 Million Registered Direct Offering
25 Mar 2024 //
GLOBENEWSWIRE
BioXcel Announces Patent Office Grant of Patent for Method of Treating Agitation
15 Mar 2024 //
GLOBENEWSWIRE
BioXcel Reports Financial Results for the Fourth Quarter and Full Year 2023
12 Mar 2024 //
GLOBENEWSWIRE
BioXcel to Report Fourth Quarter and Full Year 2023 Financial Results
01 Mar 2024 //
GLOBENEWSWIRE
BioXcel Therapeutics Announces Termination of Proposed Public Offering
13 Feb 2024 //
GLOBENEWSWIRE
BioXcel Therapeutics Receives FDA Fast Track Designation for BXCL701
12 Feb 2024 //
GLOBENEWSWIRE
BioXcel Therapeutics Announces Proposed Public Offering
08 Feb 2024 //
GLOBENEWSWIRE
BioXcel Announces Completion of Patient Enrollment in Phase 2 Trial of BXCL701
06 Feb 2024 //
GLOBENEWSWIRE
BioXcel Therapeutics Hosting Virtual Neuroscience R&D Day Today
12 Dec 2023 //
GLOBENEWSWIRE
BioXcel Strengthens Leadership to Advance Late-Stage Programs
11 Dec 2023 //
GLOBENEWSWIRE
BioXcel Therapeutics to Host Virtual Neuroscience R&D Day on Dec. 12, 2023
30 Nov 2023 //
PRESS RELEASE
BioXcel Aligns with FDA Recommendation for Phase 3 Trial for TRANQUILITY Program
14 Nov 2023 //
GLOBENEWSWIRE
BioXcel Reports Positive Overall Survival Results form Phase 2 Trial of BXCL701
08 Nov 2023 //
GLOBENEWSWIRE
BioXcel Therapeutics Announces Update on NIDA-funded Trial of BXCL501
06 Nov 2023 //
GLOBENEWSWIRE
BioXcel to Report Third Quarter 2023 Financial Results on November 14, 2023
31 Oct 2023 //
GLOBENEWSWIRE
BioXcel Therapeutics Receives Permanent J-Code for IGALMI
30 Oct 2023 //
GLOBENEWSWIRE
Despite misconduct at trial site, BioXcel touts audit`s findings
26 Oct 2023 //
FIERCE PHARMA
BioXcel Announces Findings from Audit of Data Integrity at Phase 3 Trial Site
25 Oct 2023 //
GLOBENEWSWIRE
BioXcel Reports Positive Overall Survival Results from Phase 2 Trial of BXCL701
10 Oct 2023 //
GLOBENEWSWIRE
BioXcel Provides Update on Recent Developments for IGALMI Film
04 Oct 2023 //
GLOBENEWSWIRE
BioXcel cuts 50% jobs as it pivots focus to retail market for agitation drug
15 Aug 2023 //
REUTERS
BioXcel Therapeutics Reports Second Quarter 2023 Financial Results
14 Aug 2023 //
GLOBENEWSWIRE
BioXcel to Report Second Quarter 2023 Financial Results on August 14, 2023
31 Jul 2023 //
GLOBENEWSWIRE
BioXcel shares plunge after issues at trial site for Alzheimer`s-related drug
30 Jun 2023 //
REUTERS
BioXcel Announces +ve Topline Results From TRANQUILITY II Ph 3 Trial of BXCL501
29 Jun 2023 //
GLOBENEWSWIRE
BioXcel Therapeutics to Participate at Two Upcoming Investor Conferences
01 Jun 2023 //
GLOBENEWSWIRE
BioXcel looks to expand label to at-home use for lead psych drug
25 May 2023 //
ENPTS
BioXcel Therapeutics Announces Results from SERENITY III Trial of BXCL501
25 May 2023 //
GLOBENEWSWIRE
BioXcel Announces Positive Top-Line Data from Repeat Dosing of BXCL501
16 May 2023 //
GLOBENEWSWIRE
BioXcel Therapeutics Reports 1Q 2023 FYR and Recent Operational Highlights
08 May 2023 //
GLOBENEWSWIRE
BioXcel Therapeutics to Present at BofA Securities 2023 Health Care Conference
02 May 2023 //
GLOBENEWSWIRE
BioXcel Therapeutics to Report 1Q 2023 FYR on May 8, 2023
24 Apr 2023 //
GLOBENEWSWIRE
In ‘surprise’ move, BioXcel files for cancer subsidiary to go public
16 Mar 2023 //
ENDPTS
BioXcel’s oncology spinout OnkosXcel sets out for ‘surprise’ IPO
15 Mar 2023 //
FIERCE BIOTECH
OnkosXcel Announces Confidential Submission of Draft Registration Statement
14 Mar 2023 //
GLOBENEWSWIRE
BioXcel Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results
09 Mar 2023 //
GLOBENEWSWIRE
BioXcel to Report Fourth Quarter and Full Year 2022 Financial Results
23 Feb 2023 //
GLOBENEWSWIRE
BioXcel Therapeutics to Ring Nasdaq Stock Market Closing Bell Today
21 Feb 2023 //
GLOBENEWSWIRE
BioXcel Announces Data from Phase 2 Trial of BXCL701 in Prostate Cancer
13 Feb 2023 //
GLOBENEWSWIRE
BioXcel to Host BXCL701 Leader Day to Highlight Activator for Prostate Cancer
08 Feb 2023 //
GLOBENEWSWIRE
BioXcel reports data from study of rare prostate cancer therapy
12 Jan 2023 //
CLINICAL TRIALS ARENA
